tbuckley/cabot-search huggingface dataset:
PULMONARY ARTERY TUMOR MISTAKEN AS PULMONARY THROMBUS: MULTIPARAMETRIC CARDIAC MAGNETIC RESONANCE IMAGING
Authors: Mohamed Teleb, Cristina Olivas Chacon, Luis Ramos Duran, Priyanka Wani, Kyari Sumayin Ngamdu, Wael El Mallah
Journal: Journal of the American College of Cardiology (2016)
EXAGGERATED EXERCISE BLOOD PRESSURE RESPONSE IS ACCOMPANIED BY INCREASED SYMPATHETIC ACTIVITY AND ARTERIAL STIFFNESS IN SUBJECTS WITH HIGH NORMAL BLOOD PRESSURE
Authors: Konstantinos P. Tsioufis, Theodoros Kalos, Alexandros Kasiakogias, Kyriakos Dimitriadis, Dimitris Konstantinidis, Rania Katsarou, Mairi Kouremeti, Konstantinos Kyriazopoulos, Spyros Galanakos, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2018)
TROPONIN LEVEL AT PRESENTATION IS A STRONG PREDICTOR OF OUTCOME FOR PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FOR ST ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE BLUE CROSS BLUE SHIELD OF MICHIGAN CARDIOVASCULAR COLLABORATIVE (BMC2) REGISTRY
Authors: Brett Wanamaker, Milan Seth, Devraj Sukul, Simon Dixon, Deepak Bhatt, Ryan Madder, John Rumsfeld, Hitinder Gurm
Journal: Journal of the American College of Cardiology (2018)
HMGB1 promotes ductular reaction and tumorigenesis in autophagy-deficient livers
Authors: Bilon Khambu, Nazmul Huda, Xiaoyun Chen, Daniel J. Antoine, Yong Li, Guoli Dai, Ulrike A. Köhler, Wei-Xing Zong, Satoshi Waguri, Sabine Werner, Tim D. Oury, Zheng Dong, Xiao-Ming Yin
Journal: Journal of Clinical Investigation (2018)

Autophagy is important for liver homeostasis, and the deficiency leads to injury, inflammation, ductular reaction (DR), fibrosis, and tumorigenesis. It is not clear how these events are mechanistically linked to autophagy deficiency. Here, we reveal the role of high-mobility group box 1 (HMGB1) in two of these processes. First, HMGB1 was required for DR, which represents the expansion of hepatic progenitor cells (HPCs) implicated in liver repair and regeneration. DR caused by hepatotoxic diets (3,5-diethoxycarbonyl-1,4-dihydrocollidine [DDC] or choline-deficient, ethionine-supplemented [CDE]) also depended on HMGB1, indicating that HMGB1 may be generally required for DR in various injury scenarios. Second, HMGB1 promoted tumor progression in autophagy-deficient livers. Receptor for advanced glycation end product (RAGE), a receptor for HMGB1, was required in the same two processes and could mediate the proliferative effects of HMBG1 in isolated HPCs. HMGB1 was released from autophagy-deficient hepatocytes independently of cellular injury but depended on NRF2 and the inflammasome, which was activated by NRF2. Pharmacological or genetic activation of NRF2 alone, without disabling autophagy or causing injury, was sufficient to cause inflammasome-dependent HMGB1 release. In conclusion, HMGB1 release is a critical mechanism in hepatic pathogenesis under autophagy-deficient conditions and leads to HPC expansion as well as tumor progression.
THE IMPACT OF PULMONARY HYPERTENSION ON IN-HOSPITAL OUTCOMES OF NON-ST ELEVATION MYOCARDIAL INFARCTION
Authors: Syed Ahsan, Seyed Hamed, Hosseini Dehkordi, Yumeng Wen, Shawn Lee, Farid Gholitabar, Jasjit Bhinder, Gregg Lanier
Journal: Journal of the American College of Cardiology (2018)
ALERT course (Acute Life threatening Events—Recognition and Treatment)
Authors: Tiago Villanueva
Journal: BMJ (2007)

Credit: JANHALASKA/ALAMY



FURTHER INFORMATION 

The ALERT course was designed to cater for all types of healthcare professionals, including medical students, doctors, nurses, paramedics, and resuscitation trainers. It is aimed at foundation year 1 (F1) doctors. The course is designed to teach healthcare staff to anticipate, recognise, and improve the quality of care for critically ill patients on general wards who may require subsequent admission to a critical care facility.

Being the equivalent of an F1 doctor, I …
Waking Up to the Importance of Sleep in the Pathogenesis of Alzheimer Disease
Authors: Joseph R. Winer, Bryce A. Mander
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
The return of the three wise men⇓
Authors: Nicola Sharp
Journal: BMJ (2004)

“This nonsense must stop,” said Hubert.

“Martha won't do what I tell her to,” said David Millstone and he stroked his bald head.

“You're her husband. Surely you can persuade her to attend counselling and stop drinking?”

“You don't know what it's like being married to Martha.”

“Is all not well in your marriage?”

“You're lucky. You're not married to a bigot.”

“I'll have Martha if you don't want her,” said Hubert quietly.

“Sorry, what did you say?” asked David.

“Let's focus on the main issue,” said Hubert. “The wait for an elective surgical outpatient appointment is 36 weeks. Before Martha was suspended it was four weeks.”

“More targets. All you managers ever think of is targets.”

“The inpatient waiting list is nearly two years. Martha must see patients again.”

“I really think she must stop drinking first.”

“She must start clinical work immediately. I don't care about the alcohol.”

“But this is a clinical governance issue. Think about the risks.”

There was a loud knock at the door, then the door swung open and Dr Carsington wobbled into the room with Mr Sturm on one side and Dr Urmston on the other.

“How nice to see you, gentlemen. What can I do …
Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial
Authors: Sandro Virgilio Porceddu, Mathias Bressel, Michael Geoffrey Poulsen, Adam Stoneley, Michael John Veness, Lizbeth Moira Kenny, Chris Wratten, June Corry, Stephen Cooper, Gerald Blaise Fogarty, Marnie Collins, Michael Kevin Collins, Andrew Martin John Macann, Christopher Gerard Milross, Michael Gordon Penniment, Howard Yu-hao Liu, Madeleine Trudy King, Benedict James Panizza, Danny Rischin
Journal: Journal of Clinical Oncology (2018)

Purpose To report the results of the Trans Tasman Radiation Oncology Group randomized phase III trial designed to determine whether the addition of concurrent chemotherapy to postoperative radiotherapy (CRT) improved locoregional control in patients with high-risk cutaneous squamous cell carcinoma of the head and neck. Patients and Methods The primary objective was to determine whether there was a difference in freedom from locoregional relapse (FFLRR) between 60 or 66 Gy (6 to 6.5 weeks) with or without weekly carboplatin (area under the curve 2) after resection of gross disease. Secondary efficacy objectives were to compare disease-free survival and overall survival. Results Three hundred twenty-one patients were randomly assigned, with 310 patients commencing allocated treatment (radiotherapy [RT] alone, n = 157; CRT, n = 153). Two hundred thirty-eight patients (77%) had high-risk nodal disease, 59 (19%) had high-risk primary or in-transit disease, and 13 (4%) had both. Median follow-up was 60 months. Median RT dose was 60 Gy, with 84% of patients randomly assigned to CRT completing six cycles of carboplatin. The 2- and 5-year FFLRR rates were 88% (95% CI, 83% to 93%) and 83% (95% CI, 77% to 90%), respectively, for RT and 89% (95% CI, 84% to 94%) and 87% (95% CI, 81% to 93%; hazard ratio, 0.84; 95% CI, 0.46 to 1.55; P = .58), respectively, for CRT. There were no significant differences in disease-free or overall survival. Locoregional failure was the most common site of first treatment failure, with isolated distant metastases as the first site of failure seen in 7% of both arms. Treatment was well tolerated in both arms, with no observed enhancement of RT toxicity with carboplatin. Grade 3 or 4 late toxicities were infrequent. Conclusion Although surgery and postoperative RT provided excellent FFLRR, there was no observed benefit with the addition of weekly carboplatin.
A phase II trial of consolidation nivolumab or nivolumab plus ipilimumab following concurrent chemoradiation in unresectable stage III NSCLC: BTCRC LUN16-081.
Authors: Greg Andrew Durm, Susan M. Perkins, Nasser H. Hanna
Journal: Journal of Clinical Oncology (2018)

TPS179 Background: Unresectable stage III NSCLC demonstrates poor 5-yr OS outcomes. The current standard of care for fit patients in this setting is concurrent chemoradiation. Previous studies evaluating the addition of induction or consolidation chemotherapy, EGFR-targeted agents, ant-angiogenic agents, and higher doses of radiation have failed to definitively improve OS over chemoradiation alone. Recently, a trial of consolidation PD-L1 inhibition demonstrated improved PFS over chemoradiation alone, and a second trial of consolidation PD-1 inhibition is awaiting data maturation. This may herald a change to the standard of care in this setting. The addition of CTLA-4 inhibition to anti-PD-1 monoclonal antibodies has shown improved OS in melanoma and has demonstrated encouraging early phase data in stage IV NSCLC. Therefore, we initiated a trial evaluating the addition of a CTLA-4 inhibitor to PD-1 inhibition for consolidation treatment of unresectable stage III NSCLC. Methods: This is a multi-center, randomized, phase II study of nivolumab or the combination of nivolumab and ipilimumab as consolidation therapy following concurrent chemoradiation in unresectable stage III NSCLC. Patients will receive concurrent chemoradiation with one of three standard chemotherapy backbones (Cis-Etop, Cis-Pem, or Carbo-Pac), and repeat imaging will be done 4-8 weeks following completion of therapy. Patients without progressive disease will be randomized 1:1 to receive either niv 480mg IV every 4 weeks or the combination of niv 3mg/kg IV every 2 weeks and ipi 1mg/kg IV every 6 weeks for up to 6 months. The trial will enroll a total of 108 patients with 54 in each arm. The two arms are non-comparator arms and will be compared with historical controls. The primary endpoint is the improvement of PFS at 18 months, and key secondary endpoints include OS and the toxicity of consolidation niv and niv/ipi. Exploratory endpoints will look at the correlation between multiple clinical, radiographic, and laboratory parameters and outcomes, as well as the association of these parameters with the development of pneumonitis. This trial opened to accrual in September 2017. Clinical trial information: NCT03285321.
Universal ventricular coordinates: A generic framework for describing position within the heart and transferring data
Authors: Jason Bayer, Anton J. Prassl, Ali Pashaei, Juan F. Gomez, Antonio Frontera, Aurel Neic, Gernot Plank, Edward J. Vigmond
Journal: Medical Image Analysis (2018)

Being able to map a particular set of cardiac ventricles to a generic topologically equivalent representation has many applications, including facilitating comparison of different hearts, as well as mapping quantities and structures of interest between them. In this paper we describe Universal Ventricular Coordinates (UVC), which can be used to describe position within any biventricular heart. UVC comprise four unique coordinates that we have chosen to be intuitive, well defined, and relevant for physiological descriptions. We describe how to determine these coordinates for any volumetric mesh by illustrating how to properly assign boundary conditions and utilize solutions to Laplace’s equation. Using UVC, we transferred scalar, vector, and tensor data between four unstructured ventricular meshes from three different species. Performing the mappings was very fast, on the order of a few minutes, since mesh nodes were searched in a KD tree. Distance errors in mapping mesh nodes back and forth between meshes were less than the size of an element. Analytically derived fiber directions were also mapped across meshes and compared, showing < 5° difference over most of the ventricles. The ability to transfer gradients was also demonstrated. Topologically variable structures, like papillary muscles, required further definition outside of the UVC framework. In conclusion, UVC can aid in transferring many types of data between different biventricular geometries.
Passive Detection of Atrial Fibrillation Using a Commercially Available Smartwatch
Authors: Geoffrey H. Tison, José M. Sanchez, Brandon Ballinger, Avesh Singh, Jeffrey E. Olgin, Mark J. Pletcher, Eric Vittinghoff, Emily S. Lee, Shannon M. Fan, Rachel A. Gladstone, Carlos Mikell, Nimit Sohoni, Johnson Hsieh, Gregory M. Marcus
Journal: JAMA Cardiology (2018)

<h3>Importance</h3> Atrial fibrillation (AF) affects 34 million people worldwide and is a leading cause of stroke. A readily accessible means to continuously monitor for AF could prevent large numbers of strokes and death. <h3>Objective</h3> To develop and validate a deep neural network to detect AF using smartwatch data. <h3>Design, Setting, and Participants</h3> In this multinational cardiovascular remote cohort study coordinated at the University of California, San Francisco, smartwatches were used to obtain heart rate and step count data for algorithm development. A total of 9750 participants enrolled in the Health eHeart Study and 51 patients undergoing cardioversion at the University of California, San Francisco, were enrolled between February 2016 and March 2017. A deep neural network was trained using a method called heuristic pretraining in which the network approximated representations of the R-R interval (ie, time between heartbeats) without manual labeling of training data. Validation was performed against the reference standard 12-lead electrocardiography (ECG) in a separate cohort of patients undergoing cardioversion. A second exploratory validation was performed using smartwatch data from ambulatory individuals against the reference standard of self-reported history of persistent AF. Data were analyzed from March 2017 to September 2017. <h3>Main Outcomes and Measures</h3> The sensitivity, specificity, and receiver operating characteristic C statistic for the algorithm to detect AF were generated based on the reference standard of 12-lead ECG–diagnosed AF. <h3>Results</h3> Of the 9750 participants enrolled in the remote cohort, including 347 participants with AF, 6143 (63.0%) were male, and the mean (SD) age was 42 (12) years. There were more than 139 million heart rate measurements on which the deep neural network was trained. The deep neural network exhibited a C statistic of 0.97 (95% CI, 0.94-1.00;<i>P</i> &lt; .001) to detect AF against the reference standard 12-lead ECG–diagnosed AF in the external validation cohort of 51 patients undergoing cardioversion; sensitivity was 98.0% and specificity was 90.2%. In an exploratory analysis relying on self-report of persistent AF in ambulatory participants, the C statistic was 0.72 (95% CI, 0.64-0.78); sensitivity was 67.7% and specificity was 67.6%. <h3>Conclusions and Relevance</h3> This proof-of-concept study found that smartwatch photoplethysmography coupled with a deep neural network can passively detect AF but with some loss of sensitivity and specificity against a criterion-standard ECG. Further studies will help identify the optimal role for smartwatch-guided rhythm assessment.
Abstract 15504: Time Course of Improvement of Diastolic Cardiac Function After Pulmonary Vein Isolation
Authors: Kiyoshi Masuyama, Masami Nishino, Naotaka Okamoto, Akihiro Tanaka, Naoki Mori, Nobuhiko Makino, Yasuyuki Egami, Ryu Shutta, Jun Tanouchi
Journal: Circulation (2015)

Background: Pulmonary vein isolation (PVI) is an established method of paroxysmal atrial fibrillation (PAF). It has been reported that maintenance of sinus rhythm improves diastolic cardiac function in the patients with normal ejection fraction (EF). However, it is unknown the time course of improvement of diastolic cardiac function after PVI. Methods: We enrolled 87 patients who underwent PVI for PAF and received echocardiography before and 6-month/12-month after PVI. We evaluated left ventricular diastolic dimension, EF, left atrial dimension, EF, mitral early diastolic flow velocity (E), late diastolic flow velocity (A), ratio of early diastolic transmitral flow velocity to mitral annular velocity (E/e’), deceleration time (DcT) by the echocardiography and compared the ratio of pre to 6-mounth after PVI and of 6-mounth to 12-mounth after PVI for each parameter between success group (sinus rhythm≧1year) and recurrence group. Results: E/e’ ratio decreased at 6-months after PVI in success group (62patients) than recurrence group (25patients) (0.4334±0.3584% versus 0.0369±0.1169%, p=0.01) (table) but there were no significant differences in the other analyses. In addition there were no significant differences among 6-mounth to 12-mounth parameter. Conclusion: Diastolic cardiac function, especially E/e’, can improve in the early phase (within 6 months) if the patients maintained sinus rhythm after PVI.Early follow-up of diastolic function may play an important role to find recurrence of AF.
Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era
Authors: Rebecca L. King, Grzegorz S. Nowakowski, Thomas E. Witzig, David W. Scott, Richard F. Little, Fangxin Hong, Randy D. Gascoyne, Brad S. Kahl, William R Macon
Journal: Blood Cancer Journal (2018)

Abstract ECOG/ACRIN 1412 (E1412) is a randomized, phase II open-label study of lenalidomide/RCHOP vs. RCHOP alone in adults with newly diagnosed de novo diffuse large B-cell lymphoma (DLBCL) and requires NanoString gene expression profiling (GEP) for cell-of-origin testing. Because of high ineligibility rate on retrospective expert central pathology review (ECPR), real-time (RT) ECPR was instituted to confirm diagnosis and ensure adequate tissue for GEP prior to study enrollment. Goal was notification of eligibility within 2 working days (WD). Initially, 208 patients were enrolled, 74 (35.6%) of whom were deemed ineligible by retrospective ECPR. After initiation of RT-ECPR, 219 patients were registered. Of these, 73 (33.3%) were ineligible and were declined enrollment; 47 (21.5% of total) had an ineligible diagnosis on RT-ECPR, and 26 (11.9% of total) had inadequate tissue. Because the 73 ineligible patients were never enrolled, no study slots were “lost” during this phase. Notification of eligibility occurred in an average of 1 WD (Range 0–4) with 97.3% within 2 WD. This novel RT-ECPR serves as a model for future lymphoma trials. Real-time ECPR can help to reduce costs and ensure that study slots accurately reflect the targeted population. In the precision-medicine era, rapid collection of relevant pathology/biomarker data is essential to trial success.
The Evidence for Cognitive Behavioral Therapy
Authors: Arnold A. P. van Emmerik, Kim de Jong, Stefan G. Hofmann
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients
Authors: Andrea Vergara, Catia Cilloniz, Nestor Luque, Carolina Garcia-Vidal, Javier Tejero, Rafael Perelló, Carmen María Lucena, Antoni Torres, María Angeles Marcos
Journal: European Respiratory Journal (2018)

The seroprevalence of human cytomegalovirus (CMV) is very high worldwide [1, 2] and the spectrum of disease caused by it ranges from an asymptomatic state to a mononucleosis-like syndrome to severe diseases such as pneumonia, retinitis or gastrointestinal infection. The most severe disease occurs in congenital infection and in immunosuppressed patients, in whom the virus acts as an opportunistic pathogen. However, the role of CMV in other populations is less clear and is controversial [3]. Some studies in critical patients describe a relationship between CMV and increased mortality rates, longer length of stay and prolonged need for mechanical ventilation [3–5]. The incidence of active CMV infection depends on the diagnostic method used. Several epidemiological studies and systematic reviews have assessed the incidence of CMV infection in mechanically ventilated, critically ill patients, finding values ranging from 0–36% [5–7]. In this study, we aimed to assess the incidence, clinical characteristics, risk factors and outcomes for intensive care unit (ICU) patients with CMV detection by bronchoalveolar lavage (BAL). What is the role of cytomegalovirus (CMV) in ICU patients? <http://ow.ly/GeM130holtF>
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Authors: Inhye E. Ahn, Mohammed Z. H. Farooqui, Xin Tian, Janet Valdez, Clare Sun, Susan Soto, Jennifer Lotter, Stephanie Housel, Maryalice Stetler-Stevenson, Constance M. Yuan, Irina Maric, Katherine R. Calvo, Pia Nierman, Thomas E. Hughes, Nakhle S. Saba, Gerald E. Marti, Stefania Pittaluga, Sarah E. M. Herman, Carsten U. Niemann, Lone B. Pedersen, Christian H. Geisler, Richard Childs, Georg Aue, Adrian Wiestner
Journal: Blood (2018)
ASSOCIATION OF VERY HIGH CORONARY CALCIUM SCORE WITH MAJOR ADVERSE CARDIOVASCULAR EVENTS
Authors: Mohamad Karnib, Mohammed Zaahid Sheriff, Sadeer Al-Kindi, Stan Pokras, David A. Zidar, Robert Gilkeson, Sanjay Rajagopalan, Farshad Forouzandeh
Journal: Journal of the American College of Cardiology (2018)